Forbion closes third fund on $208m

FCF III was launched in October 2014 with a $253m target, according to unquote" data. Following its predecessors, the new vehicle focuses on venture investments in European and North American companies developing drugs, medical devices and diagnostic services for the healthcare sector.

Alongside the fundraise, Forbion has hired Matthias Falcenberg as an analyst for its Munich-based investment team. Prior to the role, Falcenberg worked at the Max-Planck-Institute of Biochemistry.

Investors
FCF III secured commitments from both existing and new investors. The latter includes the European Investment Fund, the Dutch Venture Initiative, Germany's KfW development bank, pension funds, insurance companies, several European family offices and listed companies Charles River Laboratories and Knight Therapeutics.

Investments
As was the case for its predecessor, FCF III aims to invest 70% of the commitments in Europe and the remaining capital in the US and Canada. Forbion typically leads the investments' syndicates.

The fund has already invested in seven businesses, including Canadian molecular therapeutics company Engene, German RNA therapeutics business Rigontec,  UK-based oncolytic immunotherapy company Replimune, German medical devices developer Autonomic Technologies Europe, and biopharmaceutical companies Sanifit (Spain) and Akarna (UK).

People
Forbion – Sander Slootweg (managing partner).

• Tweet  
• Facebook  
• LinkedIn  
• Google plus  
• Send to  

• Topics
• Venture
• Healthcare
• Benelux
• Netherlands
• Germany